Bayer Leverages ConcertAI’s Translational360™ Platform for AI-Driven Oncology

What You Should Know:

– ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI’s Translational360 and AI SaaS solutions, which use artificial intelligence and machine learning (AI/ML)-derived insights to accelerate clinical development in precision oncology.

– The agreement will fully leverage ConcertAI’s newly launched Translational360, an integrated research-grade longitudinal clinical molecular database that taps into the CancerLinQ network of de-identified cancer patient data from over 9 million records coming from all 50 states in the U.S.

ConcertAI Advances Oncology R&D Through Integrated AI and Multi-Modal Data Solutions

ConcertAI is a leading provider of predictive and generative AI SaaS solutions, offering real-world data research tools tailored for healthcare and life sciences. Headquartered in Cambridge, MA, the company operates globally with offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. Its mission is to accelerate clinical insights and patient outcomes through research-ready data, proprietary CARAai technologies, and scientific expertise. In partnership with over 46 top biomedical innovators, 2,000 healthcare providers, and numerous medical societies, ConcertAI delivers scalable, impactful research and AI-driven solutions across the healthcare ecosystem.

Core platforms include:

• TeraRecon®, which offers advanced radiological image visualization and clinical AI decision support for MRI and CT imaging.
• CancerLinQ®, an ASCO-aligned initiative that provides oncology practices with automated QOPI and ASCO Certified® quality solutions, alongside SmartLinQ analytics services to enhance care quality and performance metrics.

A central innovation, Translational360, integrates clinical, genomic, transcriptomic, and whole-slide imaging (WSI) data derived from comprehensive molecular testing. This platform supports deeper phenotypical and genomic characterization, advancing translational research by enabling researchers to:

• Uncover disease-specific molecular mechanisms
• Understand patient-specific treatment responses
• Explore inter-patient variability crucial to novel therapeutic development

Transcriptomics, a key component of Translational360, is increasingly central to biopharma research. It enables investigators to resolve ambiguities in early-phase clinical trial outcomes by identifying both idiosyncratic positive and negative responses. Through the use of multi-modal, multi-genomic, and transcriptomic data, combined with AI-based analytics, ConcertAI supports:

• The prioritization of therapeutic programs with the highest probability of success
• The design of precision-informed clinical trials

According to Dr. Jeff Elton, CEO of ConcertAI, “This partnership advances causal biological inferences by integrating multi-modal and multi-molecular data with AI/ML-based approaches across the discovery-to-development continuum. It accelerates oncology pipelines and enables biopharma partners to deliver better medicines faster.” He emphasized that the collaboration builds on a longstanding relationship and is distinctive in its use of both tissue and liquid biopsy molecular data. This approach enables:

• AI modeling of treatment response patterns and resistance mechanisms
• Data-driven prioritization of clinical programs
• Optimization of study design based on predicted therapeutic benefit and success rates

Together, these capabilities position ConcertAI and its partners at the forefront of translational oncology innovation.